Why the immune system ages, what it costs, and why current approaches fail to address it. Immunosenescence drives 27% of age-related mortality and cascades to muscle, cognitive, and multi-system decline.
Progressive dysfunction of the immune system with age, characterized by reduced capacity to respond to new pathogens, chronic low-grade inflammation, and increased susceptibility to infection and cancer.
Senescent T-cells are lymphocytes that have reached the end of their replicative lifespan but fail to be eliminated. They accumulate with age and become the primary driver of immune dysfunction.
Telomeres too short (<3 kbp vs >10 kbp in healthy cells)
50-70% reduced killing capacity vs. healthy T-cells
Escape normal clearance mechanisms
Senescence-Associated Secretory Phenotype (SASP) drives inflammaging
10-20% at age 20 → 50-70% at age 70
Cytomegalovirus (CMV) drives T-cell exhaustion. 60-90% of adults infected. Persistent viral reactivation forces T-cells into senescence.
90% thymic involution by age 70 → reduced new T-cell production. Can't replace exhausted cells.
Senescent cells resist apoptosis and evade immune surveillance → accumulate as default.
No natural mechanism efficiently removes senescent T-cells once accumulated.
T-cells senescent by age 70
Cytotoxic capacity remaining
How immunosenescence drives systemic aging through chronic inflammation
50-70% of T-cells by age 70
IL-6, TNF-α, IL-1α, IL-8
"Inflammaging"
Vaccine efficacy drops 50-70% in elderly. Increased susceptibility to influenza, COVID-19, other infections. Reduced cancer surveillance. Paradox: Higher inflammation but lower pathogen clearance.
Can't mount adequate antibody response. 40-60% of elderly don't respond to flu vaccine vs. 90%+ in young adults.
2-3x higher infection rates. Longer recovery times. Higher mortality from infectious diseases.
Senescent glial cells (astrocytes, microglia) in the brain secrete neurotoxic SASP factors that drive neuroinflammation, synaptic loss, and cognitive impairment.
SASP-induced microglial activation releases IL-1β and TNF-α, causing synaptic pruning and neuronal damage associated with Alzheimer's pathology.
Senescent endothelial cells in cerebral vasculature impair blood-brain barrier integrity and reduce cerebral blood flow by 20-30%.
Senescent cells in skeletal muscle and satellite cells (muscle stem cells) impair regeneration, promote fibrosis, and accelerate age-related muscle loss.
Senescent satellite cells lose proliferative capacity, reducing muscle repair after injury. SASP factors inhibit myogenesis and fiber formation.
SASP-driven inflammation activates protein degradation pathways (ubiquitin-proteasome, autophagy), causing progressive muscle wasting.
The economic and human cost of immunosenescence is staggering and largely preventable
of deaths in developed countries involve immune/inflammation dysfunction. Elderly account for >80% of deaths. Most are preventable through immune restoration.
of adults >65 report functional limitations due to frailty. Cognitive decline affects ~25% of people >65. Vaccine non-responders: 40-60% of elderly.
Frailty: $160B+ annually. Cognitive impairment: $290B+ annually. Infections in elderly: $40B+ in direct healthcare costs.
Existing interventions target symptoms rather than the root cause, leaving senescent cells intact to continue driving age-related decline.
Temporarily suppress SASP-driven inflammation but don't eliminate senescent cells. Chronic use causes significant side effects (GI bleeding, immunosuppression).
Target specific inflammatory pathways but leave senescent cells intact. Expensive, require continuous administration, and increase infection risk.
Show promise but have limited efficacy (30-50% clearance), poor tissue specificity, and significant off-target effects on healthy cells.
Can slow senescent cell accumulation but cannot reverse existing burden. Compliance challenges and limited efficacy in older populations.
What needs to happen to truly address immunosenescence
Must target senescent T-cells specifically. Must spare healthy T-cells, B-cells, NK cells, platelets.
Must achieve 70-85% clearance of senescent T-cells. Must sustain clearance with minimal re-accumulation.
Must not cause organ toxicity. Must not immunosuppress. Must not cause thrombocytopenia (was major blocker for navitoclax).
Must improve immune function (primary). Must cascade to improve muscle function (secondary). Must improve cognitive function (secondary).
No drug meets all 5 requirements. This represents a massive opportunity for innovation.
To effectively address age-related decline, we need a therapeutic approach that selectively eliminates senescent cells with high efficacy, minimal off-target effects, and practical dosing requirements.
Discover Our Novel Approach